ساخت اکانت کاربری رایگان

مقالات پذیرفته شده کنگره

  • صفحه نخست
  • مقالات پذیرفته شده اولین کنگره بین المللی ژنتیک سرطان
بازنشر

  • Immunotherapy for Cervical Cancer: Mechanistic Insights, Clinical Challenges, and Synergistic Combination Paradigms

  • Mohammad Mahdi Elahiyan,1,*
    1. Student Research Committee, School of Allied Medical Sciences, Iran University of medical sciences, Tehran, Iran


  • Introduction: Cervical cancer remains the fourth most common malignancy among women globally, causing approximately 600,000 new cases and 342,000 deaths annually. Persistent infection with high-risk human papillomavirus (hrHPV) types 16 and 18 drives over 70% of cases via the oncogenic expression of viral E6 and E7 proteins. While primary prevention and screening have reduced overall burden, advanced or recurrent cervical cancer continues to pose a formidable clinical challenge. This study critically evaluates current immunotherapeutic modalities, analyzes tumor microenvironment (TME)-mediated resistance mechanisms, and outlines synergistic combination strategies to optimize therapeutic outcomes.
  • Methods: A comprehensive evidence synthesis was conducted to analyze immunotherapeutic modalities in cervical cancer. Evaluated approaches include Immune Checkpoint Inhibitors (ICIs targeting PD-1/PD-L1 and CTLA-4), therapeutic HPV vaccines (DNA, peptide, and protein-based platforms targeting E6/E7 oncoproteins), Adoptive Cell Therapies (ACT including TILs and CAR-T), non-specific immunomodulators, and combination protocols integrating immunotherapy with chemoradiotherapy.
  • Results: While immune checkpoint inhibitors (ICIs) and E6/E7-targeted therapeutic HPV vaccines reactivate host antitumor immunity, their monotherapeutic efficacy is constrained by primary resistance and tumor microenvironment (TME) immunosuppression. Adoptive cell therapies, such as tumor-infiltrating lymphocytes, demonstrate potent targeted reactivity, whereas CAR-T approaches are hampered by physical stromal barriers in solid tumors. Integrating ICIs with chemoradiotherapy yields synergistic responses by triggering immunogenic cell death and boosting T-cell infiltration. However, broader clinical application remains challenged by immune-related adverse events, TME immune evasion, high manufacturing costs, and an absence of robust predictive biomarkers.
  • Conclusion: Immunotherapy has fundamentally shifted the management paradigm for cervical cancer; nevertheless, monotherapies face significant hurdles due to TME immunosuppression. Future progress hinges on rational combination therapies, identifying robust predictive biomarkers, and modulating the physical and cellular barriers of the TME to maximize durable clinical responses.
  • Keywords: Cervical Cancer; Immunotherapy; Immune Checkpoint Inhibitors;

به خانواده بزرگ کنسر ژنتیکس و ژنومیکس سرطان بپیوندید!

ایجاد حساب کاربری رایگان